Form 4: Aileron Therapeutics Director Acquires Stock Options

Manuel Aivado, a director of Aileron Therapeutics, Inc., was granted stock options to purchase 2,725 shares of common stock on August 20, 2024.

Summary

• On August 20, 2024, Manuel Aivado, a director of Aileron Therapeutics, Inc., was granted stock options.
• The options allow him to purchase 2,725 shares of the company's common stock at an exercise price of $2.40 per share.
• The options vest fully on the earlier of August 20, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders.
• Aivado also signed a Limited Power of Attorney, appointing Brian Windsor to handle Section 16 reporting obligations related to his transactions in Aileron Therapeutics securities.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (granting of stock options) and doesn't contain any overtly positive or negative information. It's a neutral event from an investment perspective.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule provides an incentive for the director to remain with the company and contribute to its success.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in publicly traded companies, particularly in the biotech sector, to incentivize performance and align interests with shareholders.
• The vesting schedule of one year is fairly typical, although some companies may use longer or shorter vesting periods.
• The exercise price of $2.40 is relevant to the current market price of Aileron Therapeutics stock, and the potential for future gains depends on the company's performance and stock appreciation.

Stakeholder Impact

• The granting of stock options could potentially benefit shareholders if the director's performance leads to an increase in the company's stock price.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates